Development of a Kilogram-Scale Synthesis of a Key Ulevostinag Subunit Part II: An Electrophilic Approach to Fluorinated Nucleosides
作者:Andrew J. Neel、Zhuqing Liu、Tamas Benkovics、Lu Wang、Stephan M. Rummelt、Heather C. Johnson、Kevin M. Belyk、Feng Xu、Cheol K. Chung、David J. Lamberto、Ryan D. Cohen、Stephanus Axnanda、Zachary E. X. Dance
DOI:10.1021/acs.oprd.2c00395
日期:2023.3.17
interferon genes (STING) that was selected as a clinical candidate for evaluation in multiple solid tumor types. Nucleoside analogue 3′-deoxy-3′-α-fluroguanosine (3′FG) is one of two key monomeric subunits comprising Ulevostinag, and its efficient preparation was set as a key deliverable in the development of this novel therapeutic. We recently reported a novel synthetic approach to 3′FG, involving
Ulevostinag (MK-1454) 是一种有效的干扰素基因 (STING) 环状二核苷酸刺激剂,被选为多种实体瘤类型的临床候选药物。核苷类似物 3'-deoxy-3'-α-fluoroguanosine (3'FG) 是构成 Ulevostinag 的两个关键单体亚基之一,其高效制备被设定为开发这种新型疗法的关键成果。我们最近报道了一种新的 3'FG 合成方法,涉及氨基催化亲电氟化和随后的底物定向还原可分离的 2'-酮-核苷 ( i -Bu-3 )。在此,我们描述了这些关键立体定义步骤的过程开发,使i -Bu-3'FG的公斤级制备成为可能( 1). 该过程的主要特征包括 (1) 将市售l-亮氨酸酰胺鉴定为优异的氟化催化剂,(2) 从受阻核苷 β-面开发高度立体选择性 (>95:5) 的分子内氢化物递送,以及 ( 3) 使用色散拉曼光谱来指导1结晶过程中的形态控制。